SCHEMBL11516404

SCHEMBL11516404

Cc1cccc2sc(CC#N)nc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
GAA P10253 1/20 0.42
MAPT P10636 8/20 0.41
MEN1 O00255 7/20 0.40
KMT2A Q03164 7/20 0.40
TDP1 Q9NUW8 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
PKM P14618 1/20 0.40
ALOX15 P16050 3/20 0.39
LMNA P02545 2/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
PSMB8 P28062 1/20 0.37
LIPG Q9Y5X9 2/20 0.37
HPGD P15428 3/20 0.36
USP2 O75604 3/20 0.36
POLB P06746 3/20 0.36
HSD17B10 Q99714 2/20 0.36
ALOX12 P18054 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18285791 0.81 LIPG (0.49) ALDH1A1MAPTMEN1KMT2ATDP1
SCHEMBL9037145 0.81 PSMB8 (0.59) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL11515193 0.81 GAA (0.42) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL805050 0.80 ALDH1A1 (0.58) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL11514234 0.78 PSMB8 (0.39) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL28272959 0.78 ALDH1A1 (0.56) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL14127136 0.78 ALDH1A1 (0.56) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL5973543 0.78 ALDH1A1 (0.61) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL103829 0.75 ALDH1A1 (0.49) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL11512955 0.75 ALDH1A1 (0.48) ALDH1A1GAAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 US disclosed
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 US disclosed
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 US disclosed
US-20210188833-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2021-06-24 US disclosed
US-20210188833-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2021-06-24 US disclosed
US-10787444-B2 Compounds for the modulation of myc activity SYROS PHARMACEUTICALS, INC. (US) 2020-09-29 US disclosed
US-10787444-B2 Compounds for the modulation of myc activity SYROS PHARMACEUTICALS, INC. (US) 2020-09-29 US disclosed
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-06-14 US disclosed
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-06-14 US disclosed
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-06-14 US disclosed
WO-2016197078-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS, INC. (US) 2016-12-08 WO disclosed
WO-2016197078-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS, INC. (US) 2016-12-08 WO disclosed
US-4146712-A PROCESS FOR THE MANUFACTURE OF COUMARIN DYES CIBA-GEIGY CORPORATION (US) 1979-03-27 US disclosed
US-4113718-A Basic azo dyes CIBA-GEIGY CORPORATION (US) 1978-09-12 US disclosed
US-4064136-A FROM A NITRILE, AN ALCOHOL AND ORTHO-SUBSTITUTED AROMATIC AMINE CIBA-GEIGY AG (CH) 1977-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 ALDH1A1 2091/4885GAA 2497/4885MAPT 104/4885
US-20210188833-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 ALDH1A1 2768/4885GAA 2507/4885MAPT 131/4885
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 ALDH1A1 2768/4885GAA 2507/4885MAPT 131/4885
US-10787444-B2 Compounds for the modulation of myc activity MYC, MYCBP, MYCBP2 ALDH1A1 2091/4885GAA 2497/4885MAPT 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.